BRAF and neoplasm: The evaluation cohort had a similar rate of low-risk tumor classifier scores, and these were shown to be consistent even when XA was negative for a large panel of genomic variants and fusions, where BRAF-like and RAS-like molecular risk stratification cannot be invoked (Table 3c).